506 related articles for article (PubMed ID: 7474883)
21. Modulation of immune responses in mice to recombinant antigens from PE and PPE families of proteins of Mycobacterium tuberculosis by the Ribi adjuvant.
Chaitra MG; Nayak R; Shaila MS
Vaccine; 2007 Oct; 25(41):7168-76. PubMed ID: 17709160
[TBL] [Abstract][Full Text] [Related]
22. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
23. Comparison of immune and adverse effects induced by AdjuVac and Freund's complete adjuvant in New Zealand white rabbits (Oryctolagus cuniculus).
Powers JG; Nash PB; Rhyan JC; Yoder CA; Miller LA
Lab Anim (NY); 2007 Oct; 36(9):51-8. PubMed ID: 17885664
[TBL] [Abstract][Full Text] [Related]
24. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
[TBL] [Abstract][Full Text] [Related]
25. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.
Bungener L; Geeraedts F; Ter Veer W; Medema J; Wilschut J; Huckriede A
Vaccine; 2008 May; 26(19):2350-9. PubMed ID: 18400340
[TBL] [Abstract][Full Text] [Related]
26. Studies on the efficacy of different adjuvants in live stock specific bacterial vaccines for turkeys against Bordetella infection and onset of antibody titers in respect to the age of the turkey poults.
Glünder G; van der Ven H; Foulman A
Pol J Vet Sci; 2004; 7(2):77-81. PubMed ID: 15230536
[TBL] [Abstract][Full Text] [Related]
27. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.
de Wit E; Munster VJ; Spronken MI; Bestebroer TM; Baas C; Beyer WE; Rimmelzwaan GF; Osterhaus AD; Fouchier RA
J Virol; 2005 Oct; 79(19):12401-7. PubMed ID: 16160167
[TBL] [Abstract][Full Text] [Related]
28. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine.
Frey SE; Harrison C; Pass RF; Yang E; Boken D; Sekulovich RE; Percell S; Izu AE; Hirabayashi S; Burke RL; Duliège AM
J Infect Dis; 1999 Nov; 180(5):1700-3. PubMed ID: 10515836
[TBL] [Abstract][Full Text] [Related]
29. Comparative analysis of the immunostimulatory properties of different adjuvants on the immunogenicity of a prototype parainfluenza virus type 3 subunit vaccine.
Ewasyshyn M; Caplan B; Bonneau AM; Scollard N; Graham S; Usman S; Klein M
Vaccine; 1992; 10(6):412-20. PubMed ID: 1317984
[TBL] [Abstract][Full Text] [Related]
30. A serological comparison of Pasteurella haemolytica vaccines containing different adjuvants.
Wells PW; Gilmour NJ; Burrells C; Thompson DA
Res Vet Sci; 1979 Sep; 27(2):248-50. PubMed ID: 523817
[TBL] [Abstract][Full Text] [Related]
31. Potentiation of the immune response to influenza virus subunit vaccines.
Webster RG; Glezen WP; Hannoun C; Laver WG
J Immunol; 1977 Dec; 119(6):2073-7. PubMed ID: 915292
[TBL] [Abstract][Full Text] [Related]
32. Experimental squalene adjuvant. I. Preparation and testing of its effectiveness.
Süli J; Benísek Z; Eliás D; Svrcek S; Ondrejková A; Ondrejka R; Bajová V
Vaccine; 2004 Sep; 22(25-26):3464-9. PubMed ID: 15308373
[TBL] [Abstract][Full Text] [Related]
33. Identification of adjuvants that enhance the therapeutic antibody response to host IgE.
Johansson J; Ledin A; Vernersson M; Lövgren-Bengtsson K; Hellman L
Vaccine; 2004 Jul; 22(21-22):2873-80. PubMed ID: 15246623
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.
Evans JT; Cluff CW; Johnson DA; Lacy MJ; Persing DH; Baldridge JR
Expert Rev Vaccines; 2003 Apr; 2(2):219-29. PubMed ID: 12899573
[TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.
Cooper CL; Davis HL; Morris ML; Efler SM; Krieg AM; Li Y; Laframboise C; Al Adhami MJ; Khaliq Y; Seguin I; Cameron DW
Vaccine; 2004 Aug; 22(23-24):3136-43. PubMed ID: 15297066
[TBL] [Abstract][Full Text] [Related]
36. Immunological response of female macaques to the PH-20 sperm protein following injection of recombinant proteins or synthesized peptides.
Deng X; Meyers SA; Tollner TL; Yudin AI; Primakoff PD; He DN; Overstreet JW
J Reprod Immunol; 2002 Mar; 54(1-2):93-115. PubMed ID: 11839398
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the adjuvanticity of aluminum salts and their combination in hepatitis B recombinant protein vaccine in assessed mice.
Mahboubi A; Fazeli MR; Dinarvand R; Samadi N; Sharifzadeh M; Ilka H; Azadi S; Soleimanian R; Kalkouei H; Hajikhanmirzaei R; Valadkhani M
Iran J Immunol; 2008 Sep; 5(3):163-70. PubMed ID: 18791283
[TBL] [Abstract][Full Text] [Related]
38. Comparison of antibody response by use of synthetic adjuvant system and Freund complete adjuvant in rabbits.
Mallon FM; Graichen ME; Conway BR; Landi MS; Hughes HC
Am J Vet Res; 1991 Sep; 52(9):1503-6. PubMed ID: 1835325
[TBL] [Abstract][Full Text] [Related]
39. Comparison of immune response potentiation and in vivo inflammatory effects of Freund's and RIBI adjuvants in mice.
Lipman NS; Trudel LJ; Murphy JC; Sahali Y
Lab Anim Sci; 1992 Apr; 42(2):193-7. PubMed ID: 1376374
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant formulations and their mode of action.
Allison AC; Byars NE
Semin Immunol; 1990 Sep; 2(5):369-74. PubMed ID: 1966859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
